Evidence map›Paper›PMID 38937846›Full record

ArticleJournal of translational medicine2024

A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis.

Sara Palomino-Echeverria, Estefania Huergo, Asier Ortega-Legarreta, Eva M Uson Raposo, Ferran Aguilar, Carlos de la Peña-Ramirez, Cristina López-Vicario, Carlo Alessandria, Wim Laleman, Alberto Queiroz Farias and 13 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sara Palomino-EcheverriaUnit of Translational Bioinformatics, Navarrabiomed - Fundación Miguel Servet, Pamplona, Spain.ORCID 0000-0002-0451-3749
Estefania HuergoUnit of Translational Bioinformatics, Navarrabiomed - Fundación Miguel Servet, Pamplona, Spain.
Asier Ortega-LegarretaUnit of Translational Bioinformatics, Navarrabiomed - Fundación Miguel Servet, Pamplona, Spain.
Eva M Uson RaposoEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Ferran AguilarEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Carlos de la Peña-RamirezEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Cristina López-VicarioEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Carlo AlessandriaDivision of Gastroenterology and Hepatology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
Wim LalemanDepartment of Gastroenterology & Hepatology, Section of Liver & Biliopancreatic disorders and Liver Transplantation, University Hospitals Leuven, KU LEUVEN, Leuven, Belgium.
Alberto Queiroz FariasDepartment of Gastroenterology, Hospital das Clínicas, University of São Paulo School of Medicine, Paulo School, Brazil.
Richard MoreauEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Javier FernandezEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Vicente ArroyoEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Paolo CaraceniDepartment of Medical and Surgical Science, University of Bologna, Bologna, Italy.
Vincenzo LaganiBiological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Cristina Sánchez-GarridoEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Joan ClàriaEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Jesper TegnerBiological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Jonel TrebickaEuropean Foundation for the Study of Chronic Liver Failure, Barcelona, Spain.
Narsis A KianiAlgorithmic Dynamics Lab, Center for Molecular Medicine, Karolinska Institutet, Solna, Sweden.
Nuria Planell *Unit of Translational Bioinformatics, Navarrabiomed - Fundación Miguel Servet, Pamplona, Spain. nplanellpic@unav.es.
Pierre-Emmanuel Rautou *Université Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France. pierre-emmanuel.rautou@inserm.fr.
David Gomez-Cabrero *Unit of Translational Bioinformatics, Navarrabiomed - Fundación Miguel Servet, Pamplona, Spain. david.gomez.cabrero@navarra.es.

Funding

Agence Nationale pour la Recherche ANR-18-CE14-0006-01, RHU QUID-NASH, ANR-18-IDEX-0001, ANR-22-CE14-0002Foundation pour la Recherche Médicale EQU202303016287German Research Foundation 403224013 - SFB 1382 (A09)Horizon 2020 Framework Programme 847949Ministerio de Ciencia e Innovación RYC2021-032197-I
6 · The paper itself

Abstract

backgroundPatient heterogeneity poses significant challenges for managing individuals and designing clinical trials, especially in complex diseases. Existing classifications rely on outcome-predicting scores, potentially overlooking crucial elements contributing to heterogeneity without necessarily impacting prognosis.

methodsTo address patient heterogeneity, we developed ClustALL, a computational pipeline that simultaneously faces diverse clinical data challenges like mixed types, missing values, and collinearity. ClustALL enables the unsupervised identification of patient stratifications while filtering for stratifications that are robust against minor variations in the population (population-based) and against limited adjustments in the algorithm's parameters (parameter-based).

resultsApplied to a European cohort of patients with acutely decompensated cirrhosis (n = 766), ClustALL identified five robust stratifications, using only data at hospital admission. All stratifications included markers of impaired liver function and number of organ dysfunction or failure, and most included precipitating events. When focusing on one of these stratifications, patients were categorized into three clusters characterized by typical clinical features; notably, the 3-cluster stratification showed a prognostic value. Re-assessment of patient stratification during follow-up delineated patients' outcomes, with further improvement of the prognostic value of the stratification. We validated these findings in an independent prospective multicentre cohort of patients from Latin America (n = 580).

conclusionsBy applying ClustALL to patients with acutely decompensated cirrhosis, we identified three patient clusters. Following these clusters over time offers insights that could guide future clinical trial design. ClustALL is a novel and robust stratification method capable of addressing the multiple challenges of patient stratification in most complex diseases.

Indexed as

Liver CirrhosisAcute DiseaseAgedAlgorithmsCluster AnalysisCohort StudiesFemaleHumansMaleMiddle AgedPrognosisACLFCirrhosisClusteringComplex diseasesPatient heterogeneityStratificationUnsupervised learning

Identifiers

PMID38937846
PMCPMC11210156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.